CAR-Modified Dendritic Cells for Solid Tumor Immune Activation
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current immunotherapy approaches, such as checkpoint inhibitors and CAR T-cell therapy, have limited efficacy in treating solid tumors and fail to induce a durable adaptive immune response against cancer cells.
Innovation Solution
Genetically modified dendritic cells expressing a chimeric antigen receptor (CAR) with an FMS-like tyrosine kinase 3 (Flt3) signaling domain are used to target tumor cells, induce an adaptive immune response, and activate antitumor T cells.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If checkpoint inhibitors are used to release the brake on antitumor T cells, then T cell activity is enhanced, but the therapy is ineffective if patients do not already possess an adaptive antitumor T cell response
Solution Approach 1:
The patent applies preliminary action by genetically modifying dendritic cells with CARs before administering them to patients. These pre-engineered dendritic cells are designed to recognize tumor antigens and activate T cells in advance, creating the adaptive immune response that checkpoint inhibitors alone cannot induce. The dendritic cells perform the preparatory work of T cell activation and antigen presentation before the patient's immune system encounters the tumor.
Solution Approach 2:
The patent uses dendritic cells as an intermediary between the CAR technology and the patient's immune system. The dendritic cells serve as mediators that take up tumor antigens, process them, and present them to T cells through cross-presentation. This intermediary approach bridges the gap between tumor cells and T cells, enabling the induction of adaptive immune responses that neither checkpoint inhibitors nor direct CAR T cell therapy can achieve alone.
2Reliability
If CAR T cell therapy is used to target tumor cells directly, then antigen recognition is enhanced, but the therapy fails to create a durable adaptive immune response in solid tumors
Solution Approach 1:
The patent introduces dendritic cells as intermediaries that perform antigen cross-presentation to T cells. Instead of relying solely on direct CAR T cell-tumor cell interactions, the dendritic cells take up tumor antigens, process them, and present them on MHC molecules to T cells. This cross-presentation mechanism enables the generation of durable adaptive immune responses by creating T cell memory, which persists long after the initial therapy.
Solution Approach 2:
The patent adds a new dimension to CAR therapy by combining it with dendritic cell cross-presentation capabilities. Rather than relying only on the direct cytotoxic activity of CAR T cells, the system incorporates the antigen-presenting function of dendritic cells, creating a two-pronged approach that enhances both immediate tumor killing and long-term immune memory formation.
3Adaptability or versatility
If dendritic cells are used to present tumor antigens, then adaptive immune response is induced, but the dendritic cells must first phagocytose tumor cells to obtain antigens
Solution Approach 1:
The patent merges the antigen acquisition and antigen presentation functions into a single integrated system. The genetically modified dendritic cells express CARs that directly recognize and bind to tumor cells, enabling them to phagocytose tumor cells through their CAR receptors. This consolidation of functions simplifies the overall process by eliminating the need for separate antigen extraction and presentation steps.
Solution Approach 2:
The dendritic cells perform self-service by using their own CAR receptors to capture tumor cells and acquire antigens. Rather than requiring external intervention to extract antigens from tumors, the dendritic cells autonomously seek out and internalize tumor cells through CAR-mediated recognition, then process and present the antigens themselves. This self-sufficient approach reduces procedural complexity.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The modified dendritic cells effectively phagocytose tumor cells, cross-present tumor antigens, and activate T cells, leading to a tumor-reducing immune response and potential long-term immune memory against cancer cells.
Implementation Method 1
The single-chain variable fragment (scFv) in a CAR retains its antigen recognition specificity from the variable regions of the heavy and light chains of the original monoclonal antibody. Meanwhile, signal transduction of the CAR construct largely depends on the signaling domains of the original immune receptors.
Implementation Method 2
The modified dendritic cells effectively phagocytose tumor cells, cross-present tumor antigens, and activate T cells
Implementation Method 3
Successfully creating an adaptive immune response in patients would overcome the failures of both types of immunotherapy. However, achieving this remains elusive.
Data Source
AI summary
Among the various aspects of the present disclosure is the provision of compositions and methods of making modified chimeric antigen receptor dendritic cells (CAR-DCs) and methods of use thereof. CAR-DCs can be used for the treatment of tumors and cancers, particularly solid tumors (as well as liquid tumors, blood cancer, and metastatic cancer).